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Abstract 32 
 33 
Differences related to gender have long been neglected but recent 34 
investigations show that they are widespread and may be recognized with all 35 
types of omics approaches, both in tissues and in biological fluids. Our review 36 
compiles evidence collected with proteomics techniques in our species, 37 
mainly focusing on baseline parameters in non-sexual organs in healthy men 38 
and women. Data from human specimens had to be replaced with information 39 
from other mammals every time invasive procedures of sample procurement 40 
were involved. 41 
 42 
 43 
Significance 44 
 45 
As our knowledge, and the methods to build it, get refined, gender differences 46 
need to receive more and more attention, as they influence the outcome of all 47 
aspects in lifestyle, including diet, exercise and environmental factors. In turn 48 
this background modulates a differential susceptibility to some disease, or a 49 
different pathogenetic mechanism, depending on gender, and a different 50 
response to pharmacological therapy. Preparing this review we meant to raise 51 
awareness about the gender issue. We anticipate that more and more often, 52 
in the future, separate evaluations will be carried out on male and female 53 
subjects as an alternative – and an upgrade – to the current approach of 54 
reference and test groups being ‘matched for age and sex’. 55 
 56 
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1 Introduction 69 
 70 
A thorough and systematic assessment of the expression level for the 71 
product(s) of each of the protein-coding genes identified in the human 72 
genome is being carried out through the construction of a Human Protein 73 
Atlas (http://www.proteinatlas.org) as part of the HUPO endeavor 74 
(https://www.hupo.org). At the level of organ proteomes, the Atlas database 75 
contrasts testis and prostate to endometrium, ovary and placenta. No data on 76 
the contrary are reported about the occurrence of differential regulation of any 77 
protein at sites other than gonads and genitals; sex (and age) of tissue donors 78 
together with diagnosis are only included in specific histological and Ref-seq 79 
data. No sex-specific information is available either from the ProteomicsDB 80 
repository, which collects thousands of LC-MS/MS experiments involving 81 
human tissues, cell lines and body fluids to provide a draft of the human 82 
proteome [1]. 83 
Our review aims at filling this gap by compiling evidence on gender-specific 84 
differences at the proteomic level throughout organs and tissues. Such 85 
differences have been reported for dioichous plants and for many animals in 86 
all phyla. We will focus our report on humans and, to a minor extent, on 87 
laboratory animals, as their specimens are analyzed under a number of 88 
experimental settings as models of physiological and pathological conditions 89 
in our species. As we have long ago seen in our investigations [2-4] and as 90 
we summarize in Figure 1, the differences between plasma/serum and urine 91 
proteomes between males and females in one of these species, Rattus 92 
norvegicus, are so obvious that the origin of the specimens can be easily 93 
guessed from the spot pattern in a 2-DE slab. Subtler yet significant 94 
differences are observed in human body fluids and in some human and 95 
animal tissues, as we are going to detail in the following. 96 
 97 
Our reference list only contains a little more than 100 items. Indeed, on most 98 
topics, the reports pointing out gender differences, and proving some features 99 
being dependent of sex, amount to a very small fraction of the total of 100 
proteomics investigations. In some more cases, mostly dealing with the 101 
search for biomarkers of disease, the possible occurrence of gender 102 
differences was investigated and eventually ruled out: several features were 103 
thus proven independent of sex; to keep our account focused, we do not 104 
review these reports but we like to stress that relevance and reliability are 105 
equal between evidence in favor or in disfavor of a given conclusion. In most 106 
cases, however, the investigated features were made operationally 107 
independent of sex through comparison/s between/among sex-matched 108 
experimental groups; this was most often the case with difficult to obtain 109 
clinical specimens from human patients. This amounts to disregard the 110 
influence of sex, if any, and was routine till recently. Indeed, also the 111 
endeavor of gender medicine, as aiming at understanding the differences of 112 
patho-physiology, clinical signs, prevention and treatment of diseases equally 113 
represented in men and women (while not studying either gender-related 114 
diseases or diseases prevalent in one gender) [5] is rather recent and 115 
incompletely developed. In the past century, biological and chiefly 116 
pharmacological investigation in mammals used to be carried out only in 117 
males, as the cyclic changes in females connected with their reproductive 118 
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function, and the asynchrony of such changes among individuals, was 119 
resented as a confounding element. The information collected in this review 120 
provides conclusive evidence that such an approach amounts to an 121 
unacceptable oversimplification of the biological realm. The limited number of 122 
the existing reports, overall and addressing each individual topic; the lack of 123 
match for age, genetic background, lifestyle among the reference groups; the 124 
extreme variability among the experimental procedures: these are some of the 125 
reasons to define the evidence collected so far as a challenge for future 126 
endeavor rather than as the end result of past commitment. As we’ll see both 127 
listing the results in individual areas of investigation and trying to survey the 128 
body of present-day knowledge, the state of affairs allows drawing only limited 129 
conclusions about recurrent patterns or general trends. This situation urges 130 
researchers to go deeper in the assessment of gender proteomics, much 131 
beyond the current level of available data, which in many cases are best 132 
defined as preliminary. 133 
 134 
2 Genes set the scene 135 
 136 
2.1 How does it all begin? 137 
 138 
In mammals, sex development is a genetically and hormonally controlled 139 
process that includes three sequential steps (Jost paradigm [6]). The first 140 
such step is the establishment of chromosomal, or genetic, sex (XY or XX) at 141 
conception. The second corresponds to gonadal differentiation, towards the 142 
formation of either a testis in males or an ovary in females: the former is 143 
initiated, at approximately 6 to 7 weeks of human gestation, by the expression 144 
of the Y chromosome-linked sex-determining gene called SRY while the latter 145 
is the default outcome in the absence of SRY gene products. The third step 146 
corresponds to sex differentiation, and involves the development of internal 147 
and external reproductive organs and the acquisition of secondary sex 148 
characteristics. Male differentiation is controlled by three hormones produced 149 
by the testis: Mullerian-inhibiting substance, or anti-Mullerian hormone, 150 
testosterone, and insulin-like factor 3; their absence results in female 151 
differentiation [7]. 152 
Gene SRY encodes a transcription factor that is a member of the high mobility 153 
group (HMG)-box family of DNA-binding proteins; because of its function, this 154 
protein is named testis-determining factor (TDF). Mutations in the SRY gene 155 
give rise to XY females with gonadal dysgenesis (Swyer syndrome); 156 
translocation of part of the Y chromosome containing this gene to the X 157 
chromosome causes XX male syndrome 158 
(http://www.ncbi.nlm.nih.gov/gene/6736). Some hint to the mechanism of 159 
action of SRY has been gathered by investigating the effects of its 160 
overexpression in two stably transfected lines derived from human testicular 161 
embryonic cell carcinoma NT2/D1 cells [8]. Comparing protein amounts by 2-162 
DE demonstrated down-regulation of many chaperone proteins together with 163 
up-regulation of laminin, which is important for Sertoli cell differentiation, 164 
tubular formation and testis development. Transcriptomic analysis through 165 
microarray technology detected higher levels of mRNAs coding for many zinc 166 
finger proteins but lower levels for cellular growth factors. Cell growth analysis 167 
found inhibition of S or G2/M transit with arrest of the cell cycle and inhibition 168 
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of cellular proliferation. In a different perspective, the first stages of gonadal 169 
differentiation in mouse embryos, at the ages of 11.5 and 12.0 days 170 
postcoitum, were monitored by 2-DE [9]. This extensive survey, carried out by 171 
2D LC-MS/MS, led to the recognition of a few proteins (7 over a total of 1 000) 172 
as specific to testis, both adult and embryonic, vs other organs – these 173 
proteins are likely to have testis-specific roles throughout the life of the 174 
organism – and of a larger group (81 for testis and 171 for ovary) as specific 175 
to embryonic vs adult gonads – these proteins, also expressed in adult organs 176 
other than gonads, are likely to have a specific function during organogenesis. 177 
In line with the relative quiescence of the ovarian development pathway 178 
compared with the morphologically active testis pathway, male samples 179 
contained all of the identified proteins whereas female samples contained only 180 
a fraction (60%) of them; proteins common to both sexes are likely to have a 181 
generic cellular or developmental function within the gonads, whereas 182 
proteins uniquely identified in the testis (the remaining 40%) could be involved 183 
in regulating embryonic testis differentiation and development. No protein was 184 
uniquely identified in the ovary. 185 
 186 
2.2 Genetic equity through dosage compensation? 187 
 188 
While in the most ancient organisms sex is determined by environmental or 189 
social variables, chromosome-based mechanisms are at work in less ancient 190 
species, including ours. Through evolution, differentiation of dimorphic sex 191 
chromosomes from a pair of autosomes occurred in a number of independent 192 
instances, resulting in XY (or X0) systems, with heterogametic males, and in 193 
ZW (or Z0) systems, with heterogametic females. 194 
The first event in Y chromosome differentiation in our lineage [10] was a 195 
mutation in the SRY-box 3, or SOX3, gene that - not less than 180 million 196 
years ago - shifted its function from the regulation of embryonic development 197 
to a critical determinant of maleness in the form of the SRY gene. Several 198 
internal recombination events (inversions) since caused a rearrangement of 199 
gene sequence on the Y chromosome, which restricted recombination with X. 200 
Without this mechanism to preserve its integrity, Y became susceptible to 201 
deletions, and decreased in size. Despite the transfer from an autosome, 202 
some 130 million years ago, of a block of genes (a pseudo-autosomal region 203 
that extended the length of both X and Y) plus the contribution of four copies 204 
of the DAZ spermatogenesis gene, present-day human Y chromosome is only 205 
about one-third the length of its X chromosome partner.  206 
 207 
To compensate for haploinsufficiency of X-linked genes in males and to 208 
restore equal expression between the sexes, dosage-compensation 209 
mechanisms evolved, which differ between organisms. In each cell of female 210 
mammals a complex and highly coordinated epigenetic process, called X-211 
chromosome inactivation, has been demonstrated to transcriptionally silence 212 
one of the two Xs, following either an imprinted or a random pattern; the 213 
inactivated chromosome condenses into a compact heterochromatin structure 214 
(a Barr body) and is stably maintained in a silent state [11] except, about 15% 215 
of the genes in specific regions escape inactivation and an additional 10% are 216 
expressed to different extents from some inactive X chromosomes [12]. It was 217 
hypothesized that, to compensate the imbalance between monoallelic X-218 
 6 
linked expression versus biallelic autosomal expression, in all cells the per-219 
allele expression levels of X-linked genes would be up-regulated 2x (Ohno's 220 
hypothesis [13]). The assumed dosage compensation has been investigated 221 
both at the transcriptomic and at the proteomic level, leading at first to 222 
inconsistent conclusions. Indeed, RNA-seq data in various organs and in 223 
different animal species suggested that distributions of gene expression are 224 
similar between the X chromosome and the autosomes, except for 225 
reproduction-related X-linked genes not expressed in somatic tissues [14]. 226 
Instead, by directly comparing mammalian X-linked genes with their one-to-227 
one orthologs in species that diverged before the origin of the mammalian sex 228 
chromosomes, both transcriptomic and proteomic data provide evidence for 229 
expression halving of X-linked genes during evolution, with the exception of 230 
only ∼5% of genes that encode members of large protein complexes [15]. An 231 
extensive survey (on 2,400 gene products in ten tissues of 5 males and 5 232 
females, via LC/MS on proteins and library sequencing on mRNAs) on 233 
embryonic specimens (from Gallus gallus domesticus, with heterogametic ZW 234 
females) revealed a mean across tissues male-to-female expression ratio of 235 
Z-linked genes of 1.32 for proteins and of 1.29 for mRNA. The mean Z 236 
chromosome-to-autosome expression ratio was close to 1 in males and lower 237 
than 1 in females, consistent with partly reduced Z chromosome expression in 238 
females. While these results exclude a general mechanism for chromosome-239 
wide dosage compensation at translation, 30% of all proteins encoded from Z-240 
linked genes showed a significant change in the male-to-female ratio in 241 
comparison with the corresponding ratio at the RNA level: some genes 242 
showed balanced expression between sexes and some close to 2x higher 243 
expression in males [16]. Finally, as summarized in Figure 2, the evaluation of 244 
publicly available data for human samples (without sex specification in 245 
ProteomicsDB [1]) regarding more than 10,000 autosomal and ca. 300 X-246 
linked genes could find no evidence of X-chromosome dosage compensation 247 
at the protein level [17]. 248 
The above does not apply to a finite period during preimplantation 249 
development: around the blastocyst stage, before X chromosome inactivation, 250 
male and female embryos differ in their proteome and in their metabolome as 251 
a result of the activities of specific X-linked enzymes and of the effect on the 252 
metabolic pathways they regulate. Sex-specific differences in glucose and 253 
amino acid utilization have been reported for the mouse and cow blastocysts 254 
[18]. Differences are then evident in fetal cells: 2D-DIGE and MALDI-TOF MS 255 
analysis detect differential expression between male and female amniocytes 256 
for 28 unique proteins (for 5 of which - annexin A1, cathepsin D, cytoskeletal 257 
19, protein disulfide-isomerase, and vimentin – up- or down-regulation 258 
exceeds 1.5x [19]). 259 
 260 
Sex chromosome abnormalities result in two main pathological conditions. 261 
Caryotype 45, X (X monosomy) leads to Turner syndrome, which occurs in 262 
about 1 in 2,500 newborn girls, but is much more common among 263 
pregnancies that do not survive to term (miscarriages and stillbirths). 264 
Caryotype 47, XXY (sex chromosome aneuploidy) leads to Klinefelter 265 
syndrome, which affects 1 in 500 to 1,000 newborn boys. Searching the 266 
scientific literature we were unable to locate any report on the proteomic 267 
features of either tissues or body fluids in the affected individuals. Conversely, 268 
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evidence has been collected with the aim of possibly contributing to the 269 
diagnosis of pregnancies with affected fetuses. For Turner syndrome, the test 270 
sample was maternal plasma, collected during the second trimester of 271 
pregnancy. Nine proteins (afamin, C1 esterase, CD5 antigen-like, clusterin, 272 
cytochrome c oxidase subunit 3, haptoglobin, hyaluronan-binding protein 2, Ig 273 
alpha chain, and sex hormone-binding globulin) were significantly increased in 274 
the plasma of women carrying Turner syndrome fetuses, three (kininogen-1, 275 
Ig J chain, and transthyretin) were decreased [20]. For Klinefelter syndrome, 276 
the test sample was instead amniotic fluid, also collected during the second 277 
trimester of pregnancy. Three proteins (alpha-1-antitrypsin, ceruloplasmin, 278 
and zinc-alpha-2-glycoprotein) were found at higher levels, four 279 
(apolipoprotein A-I, gelsolin, plasma retinol-binding protein, and vitamin D-280 
binding protein) at lower levels in pathological than in control specimens [21]. 281 
 282 
3 Proteins make the difference 283 
 284 
3.1 Can you tell a male from a female from their proteins? 285 
 286 
3.1.1 Sex-specific pattern in plasma/serum proteome  287 
 288 
Basic information should be regarded as essential; in fact it is often despised 289 
as trivial. Along this line, the first proteomic survey on the proteome of male 290 
serum vs female serum in humans is as recent as 2010 [22]. 291 
 292 
The first investigation we like to mention, however, is the one by Silliman et al., 293 
published two years later [23]: it has a catchy subtitle – “Proteomic analyses 294 
of human plasma: Venus versus Mars” – and the outline of its experimental 295 
plan is straightforward. Five males and five nulliparous females were enrolled; 296 
the proteome of their plasma was analyzed after depleting the 14 most 297 
abundant proteins by immunoaffinity columns. Aliquots of the treated samples 298 
were separated by 1-DE, 10 gel pieces per lane were cut for tryptic digestion, 299 
and the resulting peptides were analyzed by LC-MS/MS. This protocol 300 
resulted in the identification of a total of 231 proteins; 8 of them were found to 301 
differ in abundance between the sexes – six within one order of magnitude, 302 
one within two and one within three orders. (A note of caution: The paper 303 
does not provide details either on the number of technical replicates or on the 304 
statistical treatment; the table summarizing the results does not contain either 305 
SD or CV but, for only 2 out of 10 proteins, min-max range.) 306 
 307 
Conversely, Miike et al. [22] carried out their investigation as a very accurate 308 
multistep procedure: 12 males and 12 females were enrolled; the 6 most 309 
abundant components were depleted from their serum samples and the 310 
proteins fractionated by chromatography on a reversed-phase C18 column 311 
(120 fractions/sample); the peptides from trypsin digestion were iTRAQ-312 
labeled and fractionated by chromatography (a strong cation exchanger and a 313 
C18-3 column). The final eluent was spotted on a MALDI target (191 314 
spots/fraction); finally, the parent proteins (over 4,000) were identified by 315 
MALDI-TOF MS/MS. Less than 8% of the selected hits were > 1.5 times more 316 
abundant in female than in male serum, and less than 4% were > 1.5 times 317 
more abundant in male than in female serum. The remainder 88% of the 318 
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proteins was present in equal amounts in both sex specimens. When 319 
arranged according to their function (by MetaCore software), the proteins 320 
more abundant in female serum were found to have part in cascades 321 
connected with common female diseases, whereas the proteins more 322 
abundant in male serum participated in cascades that involved male 323 
hormones. 324 
 325 
Contrary to the above, the title of the third and last paper on this topic 326 
provides little cue to the biological data it contains: “In silico instrumental 327 
response correction improves precision of label-free proteomics and accuracy 328 
of proteomics-based predictive models” [24]. Lyutvinskiy et al. describe an in 329 
silico post-processing method leading to a CV of approx. 1% in the 330 
quantitation of >100 abundant plasma proteins after trypsin digestion and LC-331 
MS/MS (apparently without any immunodepletion and/or other preliminary 332 
sample treatment/fractionation). The procedure was first applied to pooled 333 
plasma samples (from 24 healthy males versus 24 healthy females) looking 334 
for proteins with the strongest correlation, positive or negative, with sex. When 335 
using the 10 best correlating and the 10 best anti-correlating proteins from the 336 
pooled sample analysis (data in Figure 3), the model achieved 80% accuracy 337 
in sex determinations based on single analyses of individual samples. 338 
 339 
How do the three sets of differential proteins in the above reports  – collated in 340 
Supplementary Table 1 – compare with one another? Well, not much. One 341 
obvious reason is the different sample actually analyzed, whether plasma or 342 
serum, and whether whole or depleted in a varying number of abundant 343 
proteins. As implied by the term depletion (not a synonym for removal, see 344 
[25]), it is not surprising that measurable amounts of the targeted proteins can 345 
still be found in the processed samples; it sounds however incongruous that a 346 
statistically significant difference is observed for the remains of one of the 347 
depleted proteins, as it happens for albumin and Igs in [22] and alpha-1-348 
antitrypsin in [23]. In such instances, it would be sensible either to reassess 349 
the difference in the undepleted samples, or to remove the hit from the 350 
statistics. Uncertainty about the differential concentration of alpha-1-351 
antitrypsin is so extensive that it is reported as higher in females by [23] and 352 
as higher in males by [24]. For differential proteins, male/female ratios  fall in 353 
the range 0.85-1.15 in [22] and  0.25-1.75 in [24] but exceed 100% change in 354 
[22]. With sample immunodepletion, the differential items listed in [23] are 355 
secretion proteins or are associated to either the exosomes or the plasma 356 
membrane; conversely, the items listed in [22] are mainly (intra)cellular 357 
proteins. Without sample immunodepletion, all the items listed in [24] are 358 
abundant secretion proteins. This includes alpha-2-macroglobulin – which 359 
was first reported in 1967 to be higher in women than in men [26] – and 360 
albumin – whose age and gender variation was recently surveyed in > 361 
1,000,000 individuals across the UK [27] (see Figure 4). It however does not 362 
include other proteins for which there is independent evidence of variation 363 
between sexes: for instance apolipoprotein A-I [28, 29] and IgM [30], reported 364 
as being higher in females, and IgA and IgD [30], reported as being higher in 365 
males. These and other serum proteins for which it is not easy to quote recent 366 
bibliography but whose differential levels are known by all clinical biochemists 367 
are possibly missed due to inherent bias each procedure knowingly includes. 368 
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The main point is of course pretreatment of the sample and chiefly depletion 369 
of the most abundant proteins. In addition, effects of 370 
charge/size/hydrophobicity can cause some proteins/peptides from a natural 371 
mix to go undetected or to become underrepresented vs their actual 372 
concentration ([31] for 2-DE, [32] for MS): only a concurrence of contributions 373 
from various approaches, each addressing a specific set of proteins (a 374 
specific subproteome), may provide extensive, and possibly thorough, 375 
coverage. In addition to the differences in the type of sample and in the 376 
modes of its processing, the investigations we have reviewed make reference 377 
to cohorts of very different age – students in [22] and 40-60 year old in [23]; 378 
this entails differences in hormonal status within the female group, with 379 
inclusion of post-menopausal subjects in the latter but not in the former cohort. 380 
Moreover, the enrolled subjects live in different countries (Japan, U.S.A) and 381 
thus belong to different ethnical groups, with a different genetic background, 382 
and possibly – on average – with different lifestyles and different 383 
environmental exposure.  384 
 385 
In keeping with the little attention paid to basic information, changes in the 386 
proteome of woman serum along the menstrual cycle were investigated in the 387 
early ‘60s but have not been reassessed since with up-to-date procedures. 388 
Even the low-resolution, low-sensitivity techniques of decades ago could 389 
recognize at mid-cycle definite changes in total protein as well as in 390 
concentrations of albumin and globulin fractions [33]: variability of individual 391 
components is to be expected as the basis of the above. Indeed, while no 392 
systematic investigation has been recently reported on the high-to-medium 393 
abundance serum proteins, the circulating levels of a large panel of 394 
biomarkers (low-to-very-low-abundance proteins and non-protein compounds, 395 
associated with schizophrenia, major depressive disorder, and cancer) were 396 
evaluated both in males and in females while taking into account the 397 
hormonal status of the latter (cycling, follicular phase; cycling, luteal phase; on 398 
oral contraception; post-menopausal) [34]. The concentrations of 5 analytes 399 
were found to differ significantly between females in the luteal and follicular 400 
phases of the menstrual cycle; that of 26 analytes between postmenopausal 401 
females not using hormonal replacement therapy and females with menstrual 402 
cycle and of as many as 55 analytes between oral contraceptive users and 403 
females with menstrual cycle (Figure 5). To our knowledge, no in-depth 404 
investigation with up-to-date procedures has been devoted to the changes in 405 
circulating proteins across puberty, in either sex, and across menopause, in 406 
women. 407 
 408 
3.1.2 Sex-specific pattern in other biological fluids 409 
 410 
At a difference from that of other animal species, and notably from that of rats 411 
[3, 35], human urine is not an easy sample to process for proteomics 412 
investigations. From literature data (and our own experience) protein 413 
quantitation, mostly in healthy subjects, is highly unreliable for the purpose of 414 
balancing sample loads, and protein precipitation is ineffective for the purpose 415 
of sample concentration. This is possibly connected with the presence at high 416 
concentration of proteins, or better protein fragments, of few kDa in size 417 
together with interfering substances [36]. These technical limits add up to be 418 
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biological variability in the urinary protein profiles across individuals and 419 
between different days of sample collection. 420 
Following careful optimization of the procedures, an in-depth survey by Oh et 421 
al. on pooled urine samples concluded that the 2-DE patterns are almost 422 
identical for men and women [36]. Four proteins, however, were found to be 423 
male-specific (5’-AMP-activated protein kinase, beta-2 subunit; cAMP-424 
dependent protein kinase type II-b regulatory chain; tubulin alpha-1 chain; 425 
tubulin alpha-6 chain), five to be female-specific (60S acidic ribosomal protein 426 
P0; calgranulin; peptidyl-prolyl cis-trans isomerase E; similar to protein 427 
phosphatase 1, regulatory subunit 2; transthyretin). 428 
While no list of proteins present in different amounts in male and female 429 
samples was released, the conclusions of two more recent papers [37, 38] 430 
confirm the above in terms of marginal yet reliable divergence between the 431 
proteomic pattern in the two genders, as shown by Figure 6.  432 
 433 
Contrary to serum, urine proteins have been analyzed by 2-DE at different 434 
stages of the menstrual cycle, specifically mid-cycle phase, luteal phase and 435 
after 2 months of contraceptive therapy. A total of 115 protein spots were 436 
found to be differentially represented among the subgroups: 40 of them in 437 
mid-cycle vs luteal phase, 17 in luteal phase vs contraceptive therapy, 34 in 438 
mid-cycle vs contraceptive therapy and 24 in menstrual cycle (irrespective of 439 
phase) vs contraceptive therapy comparisons [39]. The proteins over-440 
represented in urine after oral contraceptive intake are apolipoprotein J, 441 
cystatin A, gelsolin, mannan-binding lectin-associated serine protease 2, 442 
S100 calcium-binding protein A9, serpin B3, tetranectin, uromodulin and Zn-443 
alpha2-glycoprotein; the under-represented proteins are serum albumin, 444 
aminoacylase 1, fatty acid-binding protein 5, perlecan and S100 calcium-445 
binding protein A8. For many of these proteins a connection is known with the 446 
effects of hormonal therapy. 447 
 448 
The investigation by Guo et al. [38] applies the same experimental scheme 449 
resulting in a clear differentiation by hierarchical clustering between male and 450 
female urines also to cerebrospinal fluid from healthy subjects of both sexes. 451 
The proteome of these samples is associated with a lower inter-individual 452 
variation than urine (18.4 vs 26.2%) and shows no remarkable inter-gender 453 
variation in humans. Contrary to our species, differences in cerebrospinal fluid 454 
proteome are observed between male and female rats [40], which are, 455 
however, less marked than those observed in serum proteome [4] or choroid 456 
plexus epithelium transcriptome [40]. As a response to male sex hormone 457 
background, four proteins (apolipoprotein A-I, insulin-like growth factor-458 
binding protein 2, or IGFBP2, prostaglandin D2 synthase, or PGDS, and 459 
transthyretin) are more concentrated in the rat CSF samples from females 460 
than in those from males. The same proteins are found at higher 461 
concentration also in samples from gonadectomized males than in those from 462 
sham-operated males; conversely, no differences are observed between 463 
sham-operated and ovariectomized females. A few more proteins are found at 464 
higher levels solely in females (fructose-bisphosphate aldolase C) or solely in 465 
gonadectomized males (transferrin and apolipoprotein E). 466 
 467 
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Saliva/oral fluids in its unstimulated and acid-stimulated composition has 468 
been recently investigated in depth by 4-plex iTRAQ 2D-LC-MS/MS. [41]. In 469 
unstimulated saliva 82 proteins, mainly associated with immune function, 470 
metabolism and inflammation were found to be gender-specific. On the 471 
contrary, no gender-specific proteins were found in acid-stimulated saliva. Sex 472 
differences in saliva proteome, however, vary by age group. Fleissig et al. 473 
consider three such ranges (22–26, 42–46, 78–88 yo). The 2-DE maps of 474 
lyophilized specimens contain 300 spots: six of them have higher intensity in 475 
young females than in young males (5x for beta-2-microglobulin and⁄or 476 
calgranulin A, 4x for transferrin and⁄or polymeric immunoglobulin receptor, 3x 477 
for calgranulin A and⁄or Ig J light chain, 2x for leukocyte elastase inhibitor and 478 
⁄ or alpha-s1-casein and an unidentified protein). In the male group, eight 479 
spots decrease in intensity with age; in the female group, two spots decrease 480 
in intensity with age, three spots increase [42]. Sun et al. study in three age 481 
groups, from children to elderly (5-7, 21-25, 65-90 yo), a specific saliva 482 
compartment, the N-glycoproteome; this was addressed by trypsin digesting 483 
the pooled concentrated samples, then enriching the glycopeptides via 484 
hydrophilic affinity and/or isolating the N-linked glycopeptides via hydrazide 485 
chemistry, and finally fractionating and identifying the peptides by LC-MS/MS. 486 
In the three test age groups, the number of N-glycoproteins specific to males 487 
is 2, 11 and 10, the number of N-glycoproteins specific to females 15, 12 and 488 
6, respectively [43]. 489 
 490 
Human (reflex) tears were analyzed by 1DLC-MS/MS, leading to the 491 
identification of 36 proteins: seven of these (alpha-1-antitrypsin, cystatin S, 492 
haptoglobin, lacritin, lactoferrrin, lipocalin, mammoglobin B), mainly involved 493 
in the local immune defense, were found at higher concentration in female 494 
than in male samples [44]. Human aqueous liquor, collected during cataract 495 
surgery, was processed through 1DE and LC-MS/MS; three proteins were 496 
found at higher concentration in female (pigment epithelium-derived factor, 497 
alpha-1-antichymotrypsin and plasma protease C1 inhibitor), one in male 498 
samples (prostaglandin-H2 D-isomerase) [45]. 499 
 500 
Evidence about some sex differences in bronchoalveolar lavage fluid 501 
(BALF) proteome is available for bovines but not for human beings. The 502 
concentration of odorant binding protein (OBP) is higher in males than in 503 
females under control conditions; following stress, it drops in males but not in 504 
females, with a specific decrease of the lower pI species [46]. 505 
 506 
3.1.3 Sex-specific patterns in tissues 507 
 508 
It comes to no surprise that the number of reports dealing with sex differences 509 
in tissues/organs under control/health conditions is very small, and evidence 510 
is limited to animals (mostly laboratory animals, some farm animal). 511 
 512 
In the skeletal muscle of exercise-naïve mice, 14% of the spots in a 2-DE 513 
map (85/608) show significant differences between genders; of these, most of 514 
the full-length identified proteins (83%) are more abundant in males, with 515 
significant but typically small (>2x) changes; only 5 proteins are more 516 
abundant in females (a G protein-coupled receptor, GRP78; the mitochondrial 517 
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proteins myoglobin, and electron transferring flavoprotein alpha; the 518 
myofibrillar proteins alpha-1 actin and desmin). As seen from the graph in 519 
Figure 7, the majority of the differential proteins have metabolic functions: 520 
decreased abundance in females applies to all identified enzymes of the 521 
glycolytic and to some of the oxidative phosphorylation pathway. Specific 522 
concentration differences also involve cytoskeletal and stress proteins; all 523 
three phosphorylation states of creatine kinase decrease in abundance in 524 
females. No clear preference is observed for the subcellular localization of the 525 
differential proteins [47]. In another species, pigs, only one skeletal muscle 526 
protein could be confirmed as differentially regulated between males and 527 
females (GDP-dissociation inhibitor 1) [48]. Again in mice but in another if 528 
related type of tissue, cardiac muscle, the number of differential proteins is 529 
comparable between sexes, if changing with age (Figure 8); it is also under 530 
obvious hormonal control, as at 6 months the number of such proteins 531 
changes from 26 (higher in males) / 35 (higher in females) of the intact mice 532 
to 26 / 16 of the castrated animals [49]. Most changes are observed for 533 
proteins involved in the maintenance of metabolic, transport and 534 
developmental processes, as well as for proteins linked to muscle contraction 535 
and energy generation; besides changes in overall abundance, in some cases 536 
a redistribution occurs among protein species. The different response of male 537 
and female murine hearts to phytoestrogen administration is assessed in [50].  538 
 539 
Sex-linked differences in mouse liver have been investigated both at the 540 
transcriptomic and at the proteomic level. The former approach evaluated 541 
14% of the detected transcripts (246/1800) as differentially expressed with 4% 542 
at higher levels in females (69/1800) and 10% in males (177/1800). Male rats 543 
have a higher expression of genes encoding important proteins for glucose 544 
oxidation, glycogen production, lipid synthesis, fatty acid oxidation, and amino 545 
acid turnover [51]. Similar findings were reported in another study for the liver 546 
proteome of euthyroid and hypothyroid animals (with more changes found in 547 
the latter, i.e. 6.7 % of overall spots/protein species changed compared to 548 
3.6 % in euthyroid animals). Authors hypothesized that these physiological 549 
differences may explain cases of different susceptibility of female rats towards 550 
exposure to lipophilic pollutants [52]. These altered pathways/proteome 551 
patterns are in agreement with the finding of a higher metabolic and growth 552 
rate and a bigger muscle mass in male rats. Among the female predominant 553 
transcripts, fatty acid translocase/CD36 has an exceptional 18x higher mRNA 554 
level in female than in male liver; such gender-differentiated expression was 555 
confirmed at the protein levels in the rat and at the mRNA level in human 556 
specimens [51]. No proteomic data are available for mouse hepatocytes as a 557 
whole but for some of their subcellular compartments such as nucleus [53], 558 
mitochondria [54] and microsomes [55]; in the latter, most of the cytochrome 559 
P450 isoforms have different expression in males and females [56]. Overall 560 
proteomic data are instead available for pig liver, in which sex-specific 561 
differences affect the levels of 4 proteins (catalase, epoxide hydrolase 1, 562 
Hsc70-interacting protein, phenylalanine-4-hydroxylase) [57]. 563 
Other reports deal with sex differences in human tissues/organs such as lung 564 
[58], primary keratinocytes [59], and adipose tissue [60]; still others with rat 565 
tissues/organs such as adipose tissue [61], forebrain ([62] actually, a 566 
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comparison between ovariectomy and estrogen replacement) and 567 
hypothalamus [63] from CNS, and lens [64] and retina [65] from the eye. 568 
In the above account we have kept details to a minimum, most often doing 569 
without lists of the affected proteins/pathways. Due to the differences in 570 
function among the various tissues and organs, the assumption of an identical 571 
set of differential proteins seems illogical and evidence demonstrates the 572 
hypothesis as untenable except for a very broad tendency of a higher 573 
capability towards energy metabolism in males. Conversely, in a few cases an 574 
at least conjectural link could be drawn between the proteomic findings and 575 
epidemiological data. One of the most interesting reports in this perspective 576 
investigates as subtle differences as PTM and their effects on the 577 
performance of mitochondrial components [66]. In rat hearts, a higher level in 578 
females than in males of the phosphorylation of two enzymes, alpha-579 
ketoglutarate dehydrogenase and aldehyde dehydrogenase 2, brings about 580 
opposite effects on their respective activities and synergistic effects on their 581 
biological functions: after PTM, the former produces lower amounts of ROS, 582 
the latter is more effective at detoxifying ROS-generated aldehyde adducts. 583 
These differences are expected to be major contributors to the higher 584 
resistance of females to the injuries from the procedures of 585 
ischemia/reperfusion in the experimental animals and to the lower risk for 586 
cardiovascular disease in human beings.  587 
The finding of differential expression of cytochrome P450 isoforms [56] may 588 
be connected with a number of distinctions between males and females: as 589 
an example, in female mice, lung microsomes contain higher amounts of 590 
CYP1A1 and liver microsomes experience a greater induction of CYP1A2 591 
after hyperoxia exposure; the gender-based female advantage is lost or 592 
reversed in Cyp1a1-/- and Cyp1a2-/- animals. Together with a number of 593 
other discriminating factors such as inflammatory and oxidative stress 594 
markers [67], this may have implications in the sex-specific differences in 595 
pulmonary morbidity in humans. 596 
 597 
4 Which differences in disease? 598 
 599 
Little more than 1% of the proteomics investigations connected with 600 
pathological conditions does differentiate test subjects on the basis of gender 601 
(https://www.ncbi.nlm.nih.gov/pubmed/). Moreover many of the relevant 602 
reports actually deal with animal models of disease rather than with clinical 603 
evidence in human patients. Finally, some of the studies do conclude that no 604 
significant difference may be observed, in the selected test samples and with 605 
the selected experimental approach, between affected males and affected 606 
females. On this basis, we have preferred to simply list in Table 1 the 607 
references we could locate in the scientific literature and to comment only on 608 
few such items. 609 
 610 
Table 1 – Gender proteomics in pathology. Differential proteomics findings between affected 611 
individuals of either gender  612 
 613 
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disease groups, by 
anatomical district or by 
pathological mechanism 
disease, or disease model references 
cancer non-small cell lung cancer [68] 
thyroid cancer [69] 
circulatory system markers of cardiovascular 
disease 
[70] 
ischemic myocardial 
infarction 
[71] 
cardiac ischemia/reperfusion (rat model) [66] 
(mouse model) [72] 
pressure overload (mouse model) [73, 74] 
cardioplegia (rabbit model) [75] 
platelets/coagulation [76-78] 
genetic disease alpha-galactosidase A 
deficiency (Anderson-Fabry 
disease) 
[79] 
galactosemia [80] 
immune system HIV [81] 
[82] 
HIV resistance [83, 84] 
Sjögren's syndrome [85] 
metabolic disease diabetes mellitus (rat model) [86] 
obesity [87-90] 
(mouse model) [91] 
(rat model) [92-96] 
nervous system Alzheimer disease [97-99] 
(mouse model) [100] 
cerebral 
ischemia/reperfusion 
(mouse model) [101, 102] 
(rat model) [103] 
neuropathic pain  (mouse model) [104] 
schizophrenia [105] 
trauma  (rat model) [106] 
urinary apparatus stress urinary incontinence (mouse model) [107, 108] 
renal ischemia/reperfusion (rat model) [109] 
 614 
The first investigation we like to single out is the Mayo Clinic proteomic 615 
markers of arteriosclerosis study [70] that enrolled at geographically distinct 616 
sites over 2,500 men and women of African-American and non-Hispanic 617 
White ethnicity belonging to sibships with at least 2 individuals diagnosed with 618 
essential hypertension prior to 60 years of age. A panel of 47 protein markers 619 
was individually measured in plasma/serum with routine clinical laboratory 620 
procedures. Differences were largely consistent across the two ethnic groups 621 
and spanned all pathways studied. Female sex was associated with higher 622 
levels of several inflammatory biomarkers (C-reactive protein, Hsp27, 623 
intercellular adhesion molecule, myeloperoxidase, advanced glycosylation 624 
end product-specific receptor, serum amyloid A), apolipoproteins (apoA-I, 625 
apoC-III, apoE, Lp(a)), larger LDL particle size, higher levels of adipokines 626 
(adiponectin, leptin and resistin), vasodilator peptides (mid-regional pro-atrial 627 
natriuretic peptide and mid-regional pro-adrenomedullin plus N-terminal pro-628 
brain-type natriuretic peptide in non-Hispanic Whites), a vasoconstrictor 629 
peptide (C-terminal pro-endothelin in non-Hispanic Whites), calcification 630 
markers (osteocalcin, osteonectin, and osteoprotegerin, in Afro-Americans) 631 
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and thrombotic markers (factors II, V, VII, and VIII, von Willebrand factor, D-632 
dimer, antithrombin III and fibrinogen). Female sex was associated with lower 633 
levels of inflammatory markers P-selectin and tissue inhibitor of 634 
metalloproteinase-1, lipoprotein-associated phospholipase A2 mass and 635 
activity, the vasoconstrictor peptide C-terminal pro-argine vasopressin and the 636 
calcification marker osteocalcin. 637 
 638 
The second investigation we deem of special interest profiled the whole 639 
serum proteomes of age-matched non-diabetic overweight (BMI >25 kg/m2) 640 
and obese (>30 and <35 kg/m2) females and males. Proteins were resolved in 641 
4 fractions by size-exclusion chromatography and analyzed by iTRAQ 2D-LC-642 
nESI-FTMS. As many as 248 proteins exhibited significantly different 643 
concentrations between men and women (p < 0.05), which mapped to 644 
pathways associated with β-estradiol, lipid and prostanoid metabolism, 645 
vitamin D function, immunity/inflammation, and the complement and 646 
coagulation cascades [87]. 647 
 648 
The two investigations have in common the epidemiological relevance of the 649 
disease under investigation and the analysis of plasma/serum components, 650 
including the major serum proteins. Everything else does differ, as Kim et al. 651 
perform routine tests for known biomarkers on a large cohort of individuals 652 
whereas Al-Daghri et al. aim at discovering differential proteomic features. 653 
What matters is that either way a number of differences are detected between 654 
males and females within the same risk or disease group. In addition to what 655 
we have already listed as for the physiological differences in healthy subjects 656 
these findings stress the interest in verifying for each condition whether or not 657 
all details of a disease are alike across genders – which might imply some 658 
consequences at the diagnostic and prognostic levels as well as imply 659 
differential requirements for therapeutic interventions. 660 
 661 
5 Conclusions 662 
 663 
Despite the comparatively low number of investigations devoted to each 664 
aspect, there is little doubt that a very high share of proteomic features does 665 
differ between male and female subjects, even when disregarding sexual 666 
organs. However, in most cases, evidence gathered thus far may only be 667 
regarded as preliminary. Heterogeneity in every aspect of the selection criteria 668 
and/or of the analytical protocols (some of which we have reported in great 669 
detail to stress this point) makes it difficult to compare results from various 670 
studies. Indeed, when we tried to find overlaps between lists of differential 671 
proteins in different reports, most often we could find none. Supplementary 672 
Table 2 collects all available data on differentially abundant proteins in tissues 673 
of healthy males and females, as quoted in 3.1.1; the list includes 178 entries 674 
and provides, with a uniform/unified layout, identification, function, origin and 675 
sex ratio for each of them. Supplementary Table 3 recapitulates the proteins 676 
for which multiple hits with identical trend were recorded (at least two entries 677 
with male/female ratio either constantly >1 or constantly <1). Only 7 proteins 678 
fulfill these criteria: carbonic anhydrase 3; cytochrome P450 2C12, female-679 
specific; cytochrome P450 2C13, male-specific; glutathione S-transferase Mu 680 
1; glutathione S-transferase Mu 2 and phytanoyl-CoA dioxygenase, 681 
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peroxisomal, found at different concentrations between males and females 682 
twice in rat liver, and L-lactate dehydrogenase, B chain, found at different 683 
concentrations between males and females once in mouse skeletal muscle 684 
once in rat cardiac muscle. Even when the findings are confirmed by duplicate 685 
studies, the quantitative data about sex imbalance vary up to over 20 fold 686 
(e.g. for carbonic anhydrase); no overlap between organs/tissue types is 687 
obvious. 688 
From Supplementary Table 2 we then extracted functional information about 689 
the differential proteins through the collection of GO terms 690 
(http://geneontology.org). Supplementary Figure 1 shows the histogram of 691 
frequencies for all the terms from all the entries, irrespective of the sample 692 
type; Supplementary Figure 2 focuses the information on proteins identified in 693 
experiments on whole tissues, as organelle subproteomes are biased by the 694 
association with specific functions. Most of the top ranking GO terms in both 695 
lists (heme and iron binding, monoxigenase activity, aromatase) describe 696 
functions connected with cytochromes, for which a sex-specific expression 697 
has been clearly documented; in turn, this implies a differential handling by 698 
tissues, and chiefly by liver, of all compounds, endogenous as well as 699 
exogenous, and is the basis for the more and more often acknowledged 700 
difference between men and women of the responses to both therapeutic 701 
treatments [110] and toxicological noxae [111]. Specifically, aromatase is the 702 
enzyme (estrogen synthetase; EC 1.14.14.1) that catalyses the synthesis of 703 
estrogens from androgens (demethylation of androgens' carbon 19 with 704 
production of phenolic 18-carbon estrogens), influencing the physiological 705 
balance between the sex steroid hormones. The enzyme is present, with 706 
tissue-specific isoforms, not only in the gonads (and in placenta) but also in 707 
brain, adipose tissue and bone; its targeted expression is controlled by a 708 
complex mechanism involving alternative promoter utilization [112]. 709 
Aromatase is known for its roles in reproduction and in reproductive system 710 
diseases (especially as a target for inhibitor therapy in estrogen-sensitive 711 
conditions). However, besides reproductive and homeostatic actions, 712 
estrogens influence cell cycle, metabolism, immunity, vasculature functions, 713 
brain development and performance, and bone remodelling. All of these 714 
aspects have a counterpat in differences between males and females in 715 
baseline indicators of health conditions as well as in disease susceptibility 716 
[113]. 717 
 718 
As an effect of the enormous variability among the procedures, the large 719 
share of potential biomarkers supposedly identified by each of the quoted 720 
reports contrasts with an extremely limited number of actually validated 721 
biomarkers. It may only be hoped that the scientific community prioritize the 722 
topic of gender-related differences in order to eventually move from the 723 
exploratory to the confirmatory phase. Although we use here the term 724 
biomarker, we mean it in the broader sense of indication of a specific 725 
condition, whether physiological or pathological. In our opinion, a clear 726 
definition of the differences between males and females, under baseline 727 
conditions, both in tissues and in biological fluids, is not for curiosity but for 728 
understanding the basics of biology in our species. To emphasize the risks of 729 
neglecting to take into account sex-related differences we like to quote the 730 
conclusions by Ramsey et al. [34] on their work on biomarkers, which shows 731 
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that as many as 96 proteins differ between men and women and, in addition, 732 
in women, 5 change along the menstrual cycle and 26 between pre-and post-733 
menopausal phases. On a technical perspective, Ramsey et al. stress that 734 
failure of matching cases and controls for sex and hormonal status during a 735 
proteomic investigation results in an unacceptably high false discovery rate, 736 
which may peak up to one order of magnitude above the outcome with 737 
properly matched groups. On a biological perspective, Ramsey et al. remark 738 
that the observed variance provides a rationale for the differences in disease 739 
susceptibility across the human population depending on sex and hormonal 740 
status. 741 
 742 
Our closing considerations go to the need for top quality investigations in a 743 
global proteomic perspective that encompasses both high and low abundance 744 
components. In our opinion biological fluids should be given the highest 745 
priority because of their relevance both in routine procedures and in research 746 
protocols. As we had mentioned in the above sections, no global investigation 747 
presently exists assessing serum composition either along the menstrual 748 
cycle or across menarche and menopause. 749 
 750 
For work on non-pathological tissues it is much more difficult to have access 751 
to human than to animal samples, and even the latter are all but trivial 752 
material. For this reason, the information obtained by processing such 753 
specimens should be pushed at the highest possible level. Both sexes should 754 
be tested – and tested separately. Also pre/post-puberty and, for women, 755 
pre/post menopause groups should be clearly divided, in order to take into 756 
account the effects of the hormonal status of the subjects. Very much is to be 757 
done to go beyond preliminary data: it should definitely be done in the next 758 
future. 759 
 760 
 761 
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We have listed at length our proteomic ‘ingredients’. A nursery rhyme has an alternative 764 
answer.  765 
 766 
What are little boys made of? 767 
What are little boys made of? 768 
Snips and snails 769 
And puppy-dogs' tails 770 
That's what little boys are made of 771 
What are little girls made of? 772 
What are little girls made of? 773 
Sugar and spice 774 
And everything nice  775 
That's what little girls are made of 776 
 777 
(Early 19th century; Roud Folk Song Index number = 821) 778 
 779 
 780 
Figure legends 781 
 782 
Figure 1 – 2-DE pattern of serum and urine from male (left) and female rats 783 
(right) as resolved on a 4-10 NL IPG and on a 7.5-17.5% T PAA gradient 784 
(modified from Figure 3 in [4]). The names of the proteins for which 785 
differences are systematically observed between genders are marked; the 786 
increase falls below 2-fold in most cases but amounts to orders of magnitude 787 
for thiostatin in female serum and for major urinary protein in male urine [2, 3]. 788 
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 789 
Figure 2 - Mean values across 17 non-sex-specific human tissues of the ratio 790 
between gene products from the X chromosome (305 genes, having excluded 791 
those known to escape from inactivation in females) and from all the 792 
autosomes (10,735 genes for which both transcriptomic and proteomic data 793 
are available). From left to right: mRNA concentration; protein concentration; 794 
protein concentration relative to mRNA concentration. The test tissues were: 795 
adipocytes, adrenal gland, bone, colon, gall bladder, heart, kidney, liver, 796 
lymph node, pancreas, salivary gland, skin, spleen, stomach, thyroid; all 797 
analyzed data refer to human samples, without sex specification, and are 798 
publicly available in ProteomicsDB [1]). Selected data redrawn from Figure 1 799 
in [17]. 800 
 801 
Figure 3 - Male/female concentration ratios for plasma proteins. Drawn from 802 
the values in the rightmost column of Table 1 in [24], set of individual LC-803 
MS/MS data, in silico corrected for the variability of the instrumental response. 804 
 805 
Figure 4 – Median serum albumin concentrations stratified into age groups of 806 
five years and male and female gender. Redrawn from data in Table 1 in [27]. 807 
 808 
Figure 5 – Top: Plot of the first two principal components from PCA on 809 
concentration data for a panel of serum biomarkers; color-coding according to 810 
sex and female hormonal status, see legend. The percentage of variation 811 
accounted for by each principal component is shown in brackets with the axis 812 
label. Modified from Figure 1 in [34]. Bottom: Number of differential 813 
biomarkers, according to sex and hormonal status, as marked. The inset 814 
inside the male vs female column specifies the number of biomarkers found at 815 
higher concentration either in males or in females. Drawn from in-text data in 816 
[34]. 817 
 818 
Figure 6 – Results from LC-MS/MS on 10 male and 10 female urine samples 819 
plus 1 pooled male urine sample (P). A: Comparison of average 820 
protein/peptide overlap rate from intra-run, intra-gender, and inter-gender 821 
urine analyses. B: Heatmap of the overlap rate between each sample pair. C: 822 
Hierarchical clustering of the samples. Redrawn from Figures 3 and 6 of [37]. 823 
 824 
Figure 7 – Grouping according to gender, function and subcellular location of 825 
the differential full-length proteins between exercise-naïve male and female 826 
murine biceps brachii. Left panel: percentage of proteins at higher 827 
concentration in males (blue) or in females (red). Redrawn from in-text data 828 
and Figure 2 of [47]. 829 
 830 
Figure 8 – Differential proteins in male (blue) and female (red) mice 831 
depending on age. Drawn from data in Table 1 of [49]. 832 
 833 
 834 
Supplementary Figure 1 - All proteins in Supplementary Table 2 were grouped 835 
by GO-Molecular Function. Entries were then classified in 2 categories: either 836 
M>F or F<M. Only groups with a significant proportion of entries with 837 
concordant ratios according to binomial test were retained. 838 
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 839 
Supplementary Figure 2 – Same as for Supplementary Figure 1, making 840 
reference only to experiments carried out on whole tissues. 841 
 842 
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